Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: BRILINTA

« Back to Dashboard

Brilinta is a drug marketed by Astrazeneca Lp and is included in one NDA. It is available from two suppliers. There are five patents protecting this drug.

The generic ingredient in BRILINTA is ticagrelor. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the ticagrelor profile page.

Summary for Tradename: BRILINTA

Patents:5
Applicants:1
NDAs:1
Suppliers: see list2

Clinical Trials for: BRILINTA

Cangrelor Ticagrelor Transition Study
Status: Completed Condition: Coronary Artery Disease

High Ticagrelor Loading Dose in STEMI
Status: Completed Condition: Coronary Artery Disease

Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients
Status: Recruiting Condition: Coronary Artery Disease

Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor
Status: Recruiting Condition: Coronary Artery Disease; Acute Coronary Syndrome

Comparison of The Influence of Ticagrelor And Clopidogrel on Inflammatory Biomarkers And Vascular Endothelial Function
Status: Not yet recruiting Condition: ST-Segment Elevation Myocardial Infarction

Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis
Status: Not yet recruiting Condition: Acute ST Segment Elevation Myocardial Infarction; Acute Coronary Syndrome

In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients
Status: Recruiting Condition: Coronary Artery Disease

Study to Assess the Effect of Ticagrelor on Coronary Blood Flow in Healthy Male Subjects.
Status: Completed Condition: Blood Flow Speed; Coronary Flow Velocity

Ticagrelor Pharmacokinetics in NSTEMI
Status: Recruiting Condition: Myocardial Infarction

Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects
Status: Recruiting Condition: Kidney Failure, Chronic

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Lp
BRILINTA
ticagrelor
TABLET;ORAL022433Jul 20, 2011RXYes6,525,060<disabled>YY<disabled>
Astrazeneca Lp
BRILINTA
ticagrelor
TABLET;ORAL022433Jul 20, 2011RXYes<disabled><disabled>
Astrazeneca Lp
BRILINTA
ticagrelor
TABLET;ORAL022433Jul 20, 2011RXYes8,425,934<disabled>Y<disabled>
Astrazeneca Lp
BRILINTA
ticagrelor
TABLET;ORAL022433Jul 20, 2011RXYes6,251,910<disabled>Y<disabled>
Astrazeneca Lp
BRILINTA
ticagrelor
TABLET;ORAL022433Jul 20, 2011RXYes7,250,419<disabled>YY<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc